Plain-English translation of NCT06770452 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called , given together with two other cancer drugs ( and chemotherapy), to see if it works better for people with advanced pancreatic cancer that has a KRAS G12D mutation. Researchers want to understand how safe this treatment combination is and whether it helps shrink tumors. The study is divided into two stages: the first stage will test the dose and watch for side effects, and if it goes well, the second stage will enroll more patients to confirm how well the medication works.
Most people with advanced pancreatic cancer have limited treatment options and don't survive very long. This medication is designed specifically to target pancreatic cancers with the KRAS G12D genetic mutation, which many patients have. By combining it with two other proven cancer drugs, researchers hope to create a more effective treatment option for this difficult-to-treat disease.
You likely qualify if…
You likely don't qualify if…
You would receive as an intravenous infusion twice per cycle (on day 1 and day 8), along with and chemotherapy drugs (albumin-bound paclitaxel and gemcitabine) on the same schedule. Each treatment cycle lasts 3 weeks, and you would continue treatment until your cancer stops responding or you develop side effects you cannot tolerate. You'll have regular clinic visits for blood tests, imaging scans, and check-ups with your medical team to monitor how well the medication is working and watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China